Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: DRUG: OLAPARIB|DRUG: Single agent chemotherapy
Sponsor: AstraZeneca
Collaborators: Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme LLC